This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arora, S. Articles by Hait, W. N. Search for Related Content PubMed PubMed Citation Articles by Arora, S. Articles by Hait, W. N.

Identification and Characterization of an Inhibitor of Eukaryotic Elongation Factor 2 Kinase against Human Cancer Cell Lines¹

The Cancer Institute of New Jersey, Departments of Medicine, Pharmacology, and Molecular Genetics, Microbiology and Immunology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901 [S. A., J-M. Y., T. G. K., P. A. O., W. N. H.], and Kinki University, Nara 631-8505 Japan [R. U., T. O., T. K.]

Recent evidence suggests that the machinery of protein synthesis may provide novel targets for anticancer drugs. For example, aberrations in protein synthesis are commonly encountered in established cancers, and disruption by mutation or overexpression of translation factors can cause cellular transformation. We previously demonstrated that the activity of eukaryotic elongation factor 2 (eEF-2) kinase was markedly increased in several forms of malignancy and that nonspecific inhibitors of this enzyme promoted cell death. On the basis of the predicted amino acid sequence of eEF-2 kinase deduced from the cloned cDNA, we hypothesized that inhibitors of prokaryotic histidine kinases might also inhibit the activity of eEF-2 kinase. We describe herein the screening of a series of imidazolium histidine kinase inhibitors and the identification of an active lead compound, NH125. NH125 inhibited eEF-2 kinase activity (IC₅₀ = 60 nM) in vitro, blocked the phosphorylation of eEF-2 in intact cells, and showed relative selectivity over other protein kinases: protein kinase C (IC₅₀ = 7.5 µM), protein kinase A (IC₅₀ = 80 µM), and calmodulin-dependent kinase II (IC₅₀ > 100 µM). NH125 decreased the viability of 10 cancer cell lines with IC₅₀s ranging from 0.7 to 4.7 µM. Forced overexpression of eEF-2 kinase in a glioma cell line produced 10-fold resistance to NH125. In conclusion, these results suggest that identification of potent inhibitors of eEF-2 kinase may lead to the development of new types of anticancer drugs.

This article has been cited by other articles:

				W. N. Hait, S. Jin, and J.-M. Yang A Matter of Life or Death (or Both): Understanding Autophagy in Cancer. Clin. Cancer Res., April 1, 2006; 12(7): 1961 - 1965. [Full Text] [PDF]

				H. Wu, J.-M. Yang, S. Jin, H. Zhang, and W. N. Hait Elongation factor-2 kinase regulates autophagy in human glioblastoma cells. Cancer Res., March 15, 2006; 66(6): 3015 - 3023. [Abstract] [Full Text] [PDF]

				S. Arora, J.-M. Yang, and W. N. Hait Identification of the Ubiquitin-Proteasome Pathway in the Regulation of the Stability of Eukaryotic Elongation Factor-2 Kinase Cancer Res., May 1, 2005; 65(9): 3806 - 3810. [Abstract] [Full Text] [PDF]

				Y. Nobukuni, K. Kohno, and K. Miyagawa Gene Trap Mutagenesis-based Forward Genetic Approach Reveals That the Tumor Suppressor OVCA1 Is a Component of the Biosynthetic Pathway of Diphthamide on Elongation Factor 2 J. Biol. Chem., March 18, 2005; 280(11): 10572 - 10577. [Abstract] [Full Text] [PDF]

				S. Arora, J.-M. Yang, R. Utsumi, T. Okamoto, T. Kitayama, and W. N. Hait P-Glycoprotein Mediates Resistance to Histidine Kinase Inhibitors Mol. Pharmacol., September 1, 2004; 66(3): 460 - 467. [Abstract] [Full Text] [PDF]